Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy

FEBS Journal

Volumn 284, Issue 1, 2017, Pages 42-55

  Sanderson, Ralph D ^a   Elkin, Michael ^b   Rapraeger, Alan C ^c   Ilan, Neta ^d   Vlodavsky, Israel ^d  

^a University of Alabama at Birmingham   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c University of Wisconsin Health   (United States)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

angiogenesis; autophagy; cancer; exosomes; heparan sulfate; heparanase; heparanase inhibitors; inflammation; metastasis; proteoglycan

Indexed keywords

ALG 2 INTERACTING PROTEIN X; GELATINASE B; HEPARANASE; HEPARANASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR 2; VERY LATE ACTIVATION ANTIGEN 4; ANTINEOPLASTIC AGENT; BETA GLUCURONIDASE; ENZYME INHIBITOR; HEPARAN SULFATE; SYNDECAN;

ANGIOGENESIS; AUTOPHAGY; CANCER CELL; CYTOKINE RELEASE; DRUG RESISTANCE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME REGULATION; EXOSOME; EXTRACELLULAR MATRIX; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; MALIGNANT NEOPLASM; METASTASIS; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; AUTOPHAGY; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; EXOSOMES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIDASE; HEPARITIN SULFATE; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; SYNDECANS;

EID: 85003881572     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13932     Document Type: Review

References (150)

1. Hammond E, Khurana A, Shridhar V & Dredge K (2014) The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. Front Oncol 4, 195.
2. Rivara S, Milazzo FM & Giannini G (2016) Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Med Chem 8, 647–680.
3. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N & Vlodavsky I (2010) Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 277, 3890–3903.
4. Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I & Pappo O (2000) Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol 157, 1167–1175.
5. Gohji K, Okamoto M, Kitazawa S, Toyoshima M, Dong J, Katsuoka Y & Nakajima M (2001) Heparanase protein and gene expression in bladder cancer. J Urol 166, 1286–1290.
6. Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, Vlodavsky I, Zimmermann A & Buchler MW (2001) Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 61, 4655–4659.
7. Marchetti D & Nicolson GL (2001) Human heparanase: a molecular determinant of brain metastasis. Adv Enzyme Regul 41, 343–359.
8. Hong X, Nelson KK, deCarvalho AC & Kalkanis SN (2010) Heparanase expression of glioma in human and animal models. J Neurosurg 113, 261–269.
9. Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA et al. (2005) Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res 11, 1028–1036.
10. Davidson B, Shafat I, Risberg B, Ilan N, Trope CG, Vlodavsky I & Reich R (2007) Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. Gynecol Oncol 104, 311–319.
11. El-Assal ON, Yamanoi A, Ono T, Kohno H & Nagasue N (2001) The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 7, 1299–1305.
12. Masola V, Maran C, Tassone E, Zin A, Rosolen A & Onisto M (2009) Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion. BMC Cancer 9, 304.
13. Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, Peretz T, Vlodavsky I & Abramovitch R (2006) Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 118, 1609–1617.
14. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F et al. (2003) High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 63, 8749–8756.
15. Masola V, Secchi MF, Gambaro G & Onisto M (2014) Heparanase as a target in cancer therapy. Curr Cancer Drug Targets 14, 286–293.
16. Pisano C, Vlodavsky I, Ilan N & Zunino F (2014) The potential of heparanase as a therapeutic target in cancer. Biochem Pharmacol 89, 12–19.
17. Vlodavsky I, Beckhove P, Lerner I, Pisano C, Meirovitz A, Ilan N & Elkin M (2012) Significance of heparanase in cancer and inflammation. Cancer Microenviron 5, 115–132.
18. Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, Pantesco V, Baudard M, De Vos J, Larroque M et al. (2007) Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109, 4914–4923.
19. Edovitsky E, Elkin M, Zcharia E, Peretz T & Vlodavsky I (2004) Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 96, 1219–1230.
20. Cassinelli G, Lanzi C, Tortoreto M, Cominetti D, Petrangolini G, Favini E, Zaffaroni N, Pisano C, Penco S, Vlodavsky I et al. (2013) Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem Pharmacol 85, 1424–1432.
21. Casu B, Vlodavsky I & Sanderson RD (2008) Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 36, 195–203.
22. Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, Brandt R, Ferro V & Bytheway I (2011) PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer 104, 635–642.
23. Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C, Carminati P, Tortoreto M et al. (2011) SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 17, 1382–1393.
24. Shafat I, Ben-Arush MW, Issakov J, Meller I, Naroditsky I, Tortoteto M, Cassinelli G, Lanzi C, Pisano C, Ilan N et al. (2010) Preclinical and clinical significance of heparanase in Ewing's sarcoma. J Cell Mol Med 15, 1857–1864.
25. Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J, Zhao G, Smith S, Galcheva-Gargova Z, Karlgren J et al. (2011) M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One 6, e21106.
26. Ramani VC, Purushothaman A, Stewart MD, Thompson CA, Vlodavsky I, Au JL & Sanderson RD (2013) The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J 280, 2294–2306.
27. McKenzie EA (2007) Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 151, 1–14.
28. Zhang YF, Tang XD, Gao JH, Fang DC & Yang SM (2011) Heparanase: a universal immunotherapeutic target in human cancers. Drug Discov Today 16, 412–417.
29. Purushothaman A, Chen L, Yang Y & Sanderson RD (2008) Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 283, 32628–32636.
30. Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC & Sanderson RD (2010) Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115, 2449–2457.
31. Ramani VC, Yang Y, Ren Y, Nan L & Sanderson RD (2011) Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem 286, 6490–6499.
32. Yang Y, Ren Y, Ramani VC, Nan L, Suva LJ & Sanderson RD (2010) Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. Cancer Res 70, 8329–8338.
33. Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I & Doweck I (2008) Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 123, 2566–2573.
34. Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy Jr JD, Sawyer J, Li JP, Zcharia E, Vlodavsky I et al. (2007) Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 282, 13326–13333.
35. Afratis NA, Nikitovic D, Multhaupt HA, Theocharis AD, Couchman JR & Karamanos NK (2016) Syndecans: key regulators of cell signaling and biological functions. FEBS J. doi:10.1111/febs.13940.
36. Simons M & Raposo G (2009) Exosomes–vesicular carriers for intercellular communication. Curr Opin Cell Biol 21, 575–581.
37. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar C et al. (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18, 883–891.
38. Peinado H, Lavotshkin S & Lyden D (2011) The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 21, 139–146.
39. Zhang HG & Grizzle WE (2011) Exosomes and cancer: a newly described pathway of immune suppression. Clin Can Res 17, 959–964.
40. Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, Ivarsson Y, Depoortere F, Coomans C, Vermeiren E et al. (2012) Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat Cell Biol 14, 677–685.
41. Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, Moita CF, Schauer K, Hume AN, Freitas RP et al. (2010) Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 12, 19–30; sup pp 1–13.
42. Roucourt B, Meeussen S, Bao J, Zimmermann P & David G (2015) Heparanase activates the syndecan-syntenin-ALIX exosome pathway. Cell Res 25, 412–428.
43. David G & Zimmermann P (2016) Heparanase tailors syndecan for exosome production. Mol Cell Oncol 3, e1047556.
44. Friand V, David G & Zimmermann P (2015) Syntenin and syndecan in the biogenesis of exosomes. Biol Cell 107, 331–341.
45. Thompson CA, Purushothaman A, Ramani VC, Vlodavsky I & Sanderson RD (2013) Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem 288, 10093–10099.
46. Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK et al. (2016) Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun 7, 11150.
47. Purushothaman A, Bandari SK, Liu J, Mobley JA, Brown EE & Sanderson RD (2016) Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome-cell Interactions. J Biol Chem 291, 1652–1663.
48. Goldshmidt O, Nadav L, Aingorn H, Irit C, Feinstein N, Ilan N, Zamir E, Geiger B, Vlodavsky I & Katz BZ (2002) Human heparanase is localized within lysosomes in a stable form. Exp Cell Res 281, 50–62.
49. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, Flugelman MY, Vlodavsky I & Ilan N (2004) Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 117, 2249–2258.
50. Gingis-Velitski S, Zetser A, Kaplan V, Ben-Zaken O, Cohen E, Levy-Adam F, Bashenko Y, Flugelman MY, Vlodavsky I & Ilan N (2004) Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem 279, 44084–44092.
51. Egeberg M, Kjeken R, Kolset SO, Berg T & Prydz K (2001) Internalization and stepwise degradation of heparan sulfate proteoglycans in rat hepatocytes. Biochim Biophys Acta 1541, 135–149.
52. Shteingauz A, Boyango I, Naroditsky I, Hammond E, Gruber M, Doweck I, Ilan N & Vlodavsky I (2015) Heparanase enhances tumor growth and chemoresistance by promoting autophagy. Cancer Res 75, 3946–3957.
53. Rosenfeldt MT & Ryan KM (2011) The multiple roles of autophagy in cancer. Carcinogenesis 32, 955–963.
54. White E (2012) Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 12, 401–410.
55. Arvatz G, Barash U, Nativ O, Ilan N & Vlodavsky I (2011) Post-transcriptional regulation of heparanase gene expression by a 3′ AU-rich element. FASEB J 24, 4969–4976.
56. Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky I & Ilan N (2008) Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res 68, 10077–10085.
57. Cohen-Kaplan V, Jrbashyan J, Yanir Y, Naroditsky I, Ben-Izhak O, Ilan N, Doweck I & Vlodavsky I (2012) Heparanase induces signal transducer and activator of transcription (STAT) protein phosphorylation: preclinical and clinical significance in head and neck cancer. J Biol Chem 287, 6668–6678.
58. Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N & Vlodavsky I (2006) Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 8, 1055–1061.
59. Fux L, Feibish N, Cohen-Kaplan V, Gingis-Velitski S, Feld S, Geffen C, Vlodavsky I & Ilan N (2009) Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res 69, 1758–1767.
60. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I & Ilan N (2006) Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 66, 1455–1463.
61. Dunlop EA & Tee AR (2014) mTOR and autophagy: a dynamic relationship governed by nutrients and energy. Semin Cell Dev Biol 36, 121–129.
62. Ramani VC, Vlodavsky I, Ng M, Zhang Y, Barbieri P, Noseda A & Sanderson RD (2016) Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype. Matrix Biol 55, 22–34.
63. Larrue C, Saland E, Boutzen H, Vergez F, David M, Joffre C, Hospital MA, Tamburini J, Delabesse E, Manenti S et al. (2016) Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Blood 127, 882–892.
64. Levy JM & Thorburn A (2011) Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther 131, 130–141.
65. Wu WK, Coffelt SB, Cho CH, Wang XJ, Lee CW, Chan FK, Yu J & Sung JJ (2012) The autophagic paradox in cancer therapy. Oncogene 31, 939–953.
66. Ilan N, Shteingauz A & Vlodavsky I (2015) Function from within: autophagy induction by HPSE/heparanase-new possibilities for intervention. Autophagy 11, 2387–2389.
67. Schaefer L, Tredup C, Gubbiotti MA & Iozzo RV (2016) Proteoglycan neofunctions: Regulation of inflammation and autophagy in cancer biology. FEBS J. doi: 10.1111/febs.13963.
68. Chaffer CL & Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331, 1559–1564.
69. Quail DF & Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19, 1423–1437.
70. Ramani VC, Pruett PS, Thompson CA, Delucas LD & Sanderson RD (2012) Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. J Biol Chem 287, 9952–9961.
71. Jung O, Trapp-Stamborski V, Purushothaman A, Jin H, Wang H, Sanderson RD & Rapraeger AC (2016) Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins. Oncogenesis 5, e202.
72. Beauvais DM, Ell BJ, McWhorter AR & Rapraeger AC (2009) Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 206, 691–705.
73. Beauvais DM, Jung O, Yang Y, Sanderson RD & Rapraeger AC (2016) Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: prevention by synstatinIGF1R inhibits tumor growth. Cancer Res 76, 4981–4993.
74. Beauvais DM & Rapraeger AC (2010) Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation. J Cell Sci 123, 3796–3807.
75. Rapraeger AC (2013) Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-alphavbeta3 integrin complex in tumorigenesis and angiogenesis. FEBS J 280, 2207–2215.
76. Wang H, Jin H & Rapraeger AC (2015) Syndecan-1 and syndecan-4 capture epidermal growth factor receptor family members and the alpha3 beta1 integrin via binding sites in their ectodomains: novel synstatins prevent kinase capture and inhibit alpha6 beta4-integrin-dependent epithelial cell motility. J Biol Chem 290, 26103–26113.
77. Van Reit I & Van Camp B (1993) The involvement of adhesion molecules in the biology of multiple myeloma. Leuk Lymphoma 9, 441–452.
78. Vande Broek I, Vanderkerken K, Van Camp B & Van Riet I (2008) Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis 25, 325–334.
79. Ramani VC, Zhan F, He J, Barbieri P, Noseda A, Tricot G & Sanderson RD (2016) Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget 7, 1598–1607.
80. Zhang L, Ngo JA, Wetzel MD & Marchetti D (2015) Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer. Neoplasia 17, 101–113.
81. Wu L, Viola CM, Brzozowski AM & Davies GJ (2015) Structural characterization of human heparanase reveals insights into substrate recognition. Nat Struct Mol Biol 22, 1016–1022.
82. Naparstek Y, Cohen IR, Fuks Z & Vlodavsky I (1984) Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature 310, 241–244.
83. Matzner Y, Bar-Ner M, Yahalom J, Ishai-Michaeli R, Fuks Z & Vlodavsky I (1985) Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes. J Clin Invest 76, 1306–1313.
84. Fridman R, Lider O, Naparstek Y, Fuks Z, Vlodavsky I & Cohen IR (1987) Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix. J Cell Physiol 130, 85–92.
85. Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, Lider O, Naparstek Y, Cohen IR & Fuks Z (1992) Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 12, 112–127.
86. Lider O, Baharav E, Mekori YA, Miller T, Naparstek Y, Vlodavsky I & Cohen IR (1989) Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest 83, 752–756.
87. Lider O, Mekori YA, Miller T, Bar-Tana R, Vlodavsky I, Baharav E, Cohen IR & Naparstek Y (1990) Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol 20, 493–499.
88. Yahalom J, Fibach E, Bar-Tana R, Fuks Z & Vlodavsky I (1988) Differentiating human leukemia cells express heparanase that degrades heparan sulfate in subendothelial extracellular matrix. Leuk Res 12, 711–717.
89. Young E (2008) The anti-inflammatory effects of heparin and related compounds. Thromb Res 122, 743–752.
90. Hershkoviz R, Mor F, Miao HQ, Vlodavsky I & Lider O (1995) Differential effects of polysulfated polysaccharide on experimental encephalomyelitis, proliferation of autoimmune T cells, and inhibition of heparanase activity. J Autoimmun 8, 741–750.
91. Parish CR, Hindmarsh EJ, Bartlett MR, Staykova MA, Cowden WB & Willenborg DO (1998) Treatment of central nervous system inflammation with inhibitors of basement membrane degradation. Immunol Cell Biol 76, 104–113.
92. Irony-Tur-Sinai M, Vlodavsky I, Ben-Sasson SA, Pinto F, Sicsic C & Brenner T (2003) A synthetic heparin-mimicking polyanionic compound inhibits central nervous system inflammation. J Neurol Sci 206, 49–57.
93. Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I & Elkin M (2006) Role of endothelial heparanase in delayed-type hypersensitivity. Blood 107, 3609–3616.
94. Floer M, Gotte M, Wild MK, Heidemann J, Gassar ES, Domschke W, Kiesel L, Luegering A & Kucharzik T (2010) Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. Am J Pathol 176, 146–157.
95. Gotte M (2003) Syndecans in inflammation. FASEB J 17, 575–591.
96. Wang L, Fuster M, Sriramarao P & Esko JD (2005) Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 6, 902–910.
97. Parish CR (2006) The role of heparan sulphate in inflammation. Nat Rev Immunol 6, 633–643.
98. Taylor KR & Gallo RL (2006) Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 20, 9–22.
99. Bode L, Salvestrini C, Park PW, Li JP, Esko JD, Yamaguchi Y, Murch S & Freeze HH (2008) Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest 118, 229–238.
100. Axelsson J, Xu D, Kang BN, Nussbacher JK, Handel TM, Ley K, Sriramarao P & Esko JD (2012) Inactivation of heparan sulfate 2-O-sulfotransferase accentuates neutrophil infiltration during acute inflammation in mice. Blood 120, 1742–1751.
101. Brunn GJ, Bungum MK, Johnson GB & Platt JL (2005) Conditional signaling by Toll-like receptor 4. FASEB J 19, 872–874.
102. Johnson GB, Brunn GJ, Kodaira Y & Platt JL (2002) Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 168, 5233–5239.
103. Akbarshahi H, Axelsson JB, Said K, Malmstrom A, Fischer H & Andersson R (2011) TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated. J Transl Med 9, 219.
104. Baker AB, Groothuis A, Jonas M, Ettenson DS, Shazly T, Zcharia E, Vlodavsky I, Seifert P & Edelman ER (2009) Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circ Res 104, 380–387.
105. Quaglio AE, Castilho AC & Di Stasi LC (2015) Experimental evidence of heparanase, Hsp70 and NF-kappaB gene expression on the response of anti-inflammatory drugs in TNBS-induced colonic inflammation. Life Sci 141, 179–187.
106. Lerner I, Hermano E, Zcharia E, Rodkin D, Bulvik R, Doviner V, Rubinstein AM, Ishai-Michaeli R, Atzmon R, Sherman Y et al. (2011) Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest 121, 1709–1721.
107. Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, Zemans RL, Bowman JC, Koyanagi DE, Yunt ZX et al. (2012) The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med 18, 1217–1223.
108. Ziolkowski AF, Popp SK, Freeman C, Parish CR & Simeonovic CJ (2012) Heparan sulfate and heparanase play key roles in mouse beta cell survival and autoimmune diabetes. J Clin Invest 122, 132–141.
109. Li RW, Freeman C, Yu D, Hindmarsh EJ, Tymms KE, Parish CR & Smith PN (2008) Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis. Arthritis Rheum 58, 1590–1600.
110. Morris A, Wang B, Waern I, Venkatasamy R, Page C, Schmidt EP, Wernersson S, Li JP & Spina D (2015) The role of heparanase in pulmonary cell recruitment in response to an allergic but not non-allergic stimulus. PLoS One 10, e0127032.
111. Puerta-Guardo H, Glasner DR & Harris E (2016) Dengue virus NS1 disrupts the endothelial glycocalyx, leading to hyperpermeability. PLoS Pathog 12, e1005738.
112. Lapidot M, Barash U, Zohar Y, Geffen Y, Naroditsky I, Ilan N, Best LA & Vlodavsky I (2015) Involvement of heparanase in empyema: implication for novel therapeutic approaches. J Clin Cell Immunol 6, pii:290.
113. Waterman M, Ben-Izhak O, Eliakim R, Groisman G, Vlodavsky I & Ilan N (2007) Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod Pathol 20, 8–14.
114. Chen G, Wang D, Vikramadithyan R, Yagyu H, Saxena U, Pillarisetti S & Goldberg IJ (2004) Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry 43, 4971–4977.
115. Binder Gallimidi A, Fischman S, Revach B, Bulvik R, Maliutina A, Rubinstein AM, Nussbaum G & Elkin M (2015) Periodontal pathogens Porphyromonas gingivalis and Fusobacterium nucleatum promote tumor progression in an oral-specific chemical carcinogenesis model. Oncotarget 6, 22613–22623.
116. Wang F, Wang Y, Zhang D, Puthanveetil P, Johnson JD & Rodrigues B (2012) Fatty acid-induced nuclear translocation of heparanase uncouples glucose metabolism in endothelial cells. Arterioscler Thromb Vasc Biol 32, 406–414.
117. He YQ, Sutcliffe EL, Bunting KL, Li J, Goodall KJ, Poon IK, Hulett MD, Freeman C, Zafar A, McInnes RL et al. (2012) The endoglycosidase heparanase enters the nucleus of T lymphocytes and modulates H3 methylation at actively transcribed genes via the interplay with key chromatin modifying enzymes. Transcription 3, 130–145.
118. Blich M, Golan A, Arvatz G, Sebbag A, Shafat I, Sabo E, Cohen-Kaplan V, Petcherski S, Avniel-Polak S, Eitan A et al. (2013) Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol 33, 56–65.
119. Massena S, Christoffersson G, Hjertstrom E, Zcharia E, Vlodavsky I, Ausmees N, Rolny C, Li JP & Phillipson M (2010) A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils. Blood 116, 1924–1931.
120. Blich M, Golan A, Arvatz G, Sebbag A, Shafat I, Sabo E, Cohen-Kaplan V, Petcherski S, Avniel-Polak S, Eitan A et al. (2012) Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol 33, 56–65.
121. Benhamron S, Nechushtan H, Verbovetski I, Krispin A, Abboud-Jarrous G, Zcharia E, Edovitsky E, Nahari E, Peretz T, Vlodavsky I et al. (2006) Translocation of active heparanase to cell surface regulates degradation of extracellular matrix heparan sulfate upon transmigration of mature monocyte-derived dendritic cells. J Immunol 176, 6417–6424.
122. Benhamron S, Reiner I, Zcharia E, Atallah M, Grau A, Vlodavsky I & Mevorach D (2012) Dissociation between mature phenotype and impaired transmigration in dendritic cells from heparanase-deficient mice. PLoS One 7, e35602.
123. Wang B, Jia J, Zhang X, Zcharia E, Vlodavsky I, Pejler G & Li JP (2011) Heparanase affects secretory granule homeostasis of murine mast cells through degrading heparin. J Allergy Clin Immunol 128, 1310–1317 e8.
124. Poon IK, Goodall KJ, Phipps S, Chow JD, Pagler EB, Andrews DM, Conlan CL, Ryan GF, White JA, Wong MK et al. (2014) Mice deficient in heparanase exhibit impaired dendritic cell migration and reduced airway inflammation. Eur J Immunol 44, 1016–1030.
125. Petrovich E, Feigelson SW, Stoler-Barak L, Hatzav M, Solomon A, Bar-Shai A, Ilan N, Li JP, Engelhardt B, Vlodavsky I et al. (2016) Lung ICAM-1 and ICAM-2 support spontaneous intravascular effector lymphocyte entrapment but are not required for neutrophil entrapment or emigration inside endotoxin-inflamed lungs. FASEB J 30, 1767–1778.
126. Weinbaum S, Tarbell JM & Damiano ER (2007) The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng 9, 121–167.
127. Constantinescu AA, Vink H & Spaan JA (2003) Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler Thromb Vasc Biol 23, 1541–1547.
128. Sue M, Higashi N, Shida H, Kogane Y, Nishimura Y, Adachi H, Kolaczkowska E, Kepka M, Nakajima M & Irimura T (2016) An iminosugar-based heparanase inhibitor heparastatin (SF4) suppresses infiltration of neutrophils and monocytes into inflamed dorsal air pouches. Int Immunopharmacol 35, 15–21.
129. Li L, Wang B, Gao T, Zhang X, Hao JX, Vlodavsky I, Wiesenfeld-Hallin Z, Xu XJ & Li JP (2012) Heparanase overexpression reduces carrageenan-induced mechanical and cold hypersensitivity in mice. Neurosci Lett 511, 4–7.
130. Zhang X, Wang B, O'Callaghan P, Hjertstrom E, Jia J, Gong F, Zcharia E, Nilsson LN, Lannfelt L, Vlodavsky I et al. (2012) Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-beta in murine brain. Acta Neuropathol 124, 465–478.
131. Escobar Galvis ML, Jia J, Zhang X, Jastrebova N, Spillmann D, Gottfridsson E, van Kuppevelt TH, Zcharia E, Vlodavsky I, Lindahl U et al. (2007) Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate. Nat Chem Biol 3, 773–778.
132. Goldberg R, Rubinstein AM, Gil N, Hermano E, Li JP, van der Vlag J, Atzmon R, Meirovitz A & Elkin M (2014) Role of heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy. Diabetes 63, 4302–4313.
133. Hermano E, Meirovitz A, Meir K, Nussbaum G, Appelbaum L, Peretz T & Elkin M (2014) Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme. J Natl Cancer Inst 106, doi: 10.1093/jnci/dju332.
134. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I & Vlodavsky I (2001) Heparanase as mediator of angiogenesis: mode of action. FASEB J 15, 1661–1663.
135. Kato M, Wang H, Kainulainen V, Fitzgerald ML, Ledbetter S, Ornitz DM & Bernfield M (1998) Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 4, 691–697.
136. Goodall KJ, Poon IK, Phipps S & Hulett MD (2014) Soluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4. PLoS One 9, e109596.
137. Yu L, Wang L & Chen S (2010) Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med 14, 2592–2603.
138. Simeonovic CJ, Ziolkowski AF, Wu Z, Choong FJ, Freeman C & Parish CR (2013) Heparanase and autoimmune diabetes. Front Immunol 4, 471.
139. Wang F, Wan A & Rodrigues B (2013) The function of heparanase in diabetes and its complications. Can J Diabetes 37, 332–338.
140. Abu El-Asrar AM, Alam K, Nawaz MI, Mohammad G, Van den Eynde K, Siddiquei MM, Mousa A, De Hertogh G, Geboes K & Opdenakker G (2015) Upregulated expression of heparanase in the vitreous of patients with proliferative diabetic retinopathy originates from activated endothelial cells and leukocytes. Invest Ophthalmol Vis Sci 56, 8239–8247.
141. Lim AK & Tesch GH (2012) Inflammation in diabetic nephropathy. Mediators Inflamm 2012, 146154.
142. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M & Garcia-Perez J (2011) Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 7, 327–340.
143. Tesch GH (2010) Macrophages and diabetic nephropathy. Semin Nephrol 30, 290–301.
144. You H, Gao T, Cooper TK, Reeves WB & Awad AS (2013) Macrophages directly mediate diabetic renal injury. Am J Physiol Renal Physiol 305, F1719–F1727.
145. Shanmugam N, Reddy MA, Guha M & Natarajan R (2003) High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 52, 1256–1264.
146. Vlassara H, Brownlee M, Manogue KR, Dinarello CA & Pasagian A (1988) Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240, 1546–1548.
147. Chow FY, Nikolic-Paterson DJ, Atkins RC & Tesch GH (2004) Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant 19, 2987–2996.
148. Poteser M & Wakabayashi I (2004) Serum albumin induces iNOS expression and NO production in RAW 267.4 macrophages. Br J Pharmacol 143, 143–151.
149. Cha JJ, Hyun YY, Lee MH, Kim JE, Nam DH, Song HK, Kang YS, Lee JE, Kim HW, Han JY et al. (2013) Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice. Endocrinology 154, 2144–2155.
150. Soldatos G & Cooper ME (2008) Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract 82 (Suppl 1), S75–S79.